Program
setmelanotide
Also written as “Setmelanotide”, “RM-493” and “Setmelanotide 2 mg”.
Its studies are mostly in Obesity · Sexual Infantilism · Prader-Willi Syndrome · Overweight · Hypertriglyceridemia, led by Rhythm Pharmaceuticals.
Furthest: phase 4, since Jul 30, 202122 company-led studies, 3 open or runningNext primary completion: Mar 13, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Rhythm Pharmaceuticals | 223 open or running | phase 4since Jul 30, 2021 | Dec 11, 2012 | Mar 13, 2027phase 3 · NCT06760546 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Dec 11, 2012.
- Sep 14, 2017Phase 3 study in ObesityNCT03287960 · 15 enrolled · Canada, France, Germany and more
- Jan 18, 2018Phase 3 study in ObesityNCT03651765 · 205 enrolled · United States, Canada, France and more
- Nov 15, 2018Phase 3 study in Bardet-Biedl SyndromeNCT03746522 · 52 enrolled · United States, Canada, France and more
- Mar 30, 2020Phase 1 study in Renal InsufficiencyNCT04348175 · 32 enrolled · United States
- Jan 6, 2021Phase 2 study in Sexual InfantilismNCT04725240 · 18 enrolled · United States
- Mar 29, 2021Phase 3 study in Bardet-Biedl SyndromeNCT04966741 · 12 enrolled · United States, Australia, Spain and more
- Jun 28, 2021Phase 2 study in Genetic ObesityNCT04963231 · 164 enrolled · United States, Canada, Germany and more
- Jul 27, 2021Phase 3 study in Bardet-Biedl SyndromeNCT05194124 · 19 enrolled · United States, Canada, Germany and more
- Jul 30, 2021Phase 4 study in HealthyNCT05046132 · 77 enrolled · United States
- Sep 30, 2021Phase 3 study in ObesityNCT05093634 · 296 enrolled · United States, Canada, France and more
- Mar 1, 2023Phase 3 study in Sexual InfantilismNCT05774756 · 143 enrolled · United States, Canada, Germany and more
- Sep 10, 2024Phase 3 study in ObesityNCT06596135 · 28 enrolled · United States
- Dec 31, 2024Phase 3 study in Sexual InfantilismNCT06760546 · 39 planned · United States, United Kingdom
- Jan 10, 2025Phase 2 study in Prader-Willi SyndromeNCT06772597 · 18 enrolled · United States
Ahead
- Nov 3, 2026Primary completion: phase 2 study in Prader-Willi SyndromeNCT06772597
- Mar 13, 2027Primary completion: phase 3 study in Sexual InfantilismNCT06760546
TargetBeta
MC4R →read by rule
“Melanocortin receptor 4 agonist; Melanocortin receptor 4 agonist”ChEMBL 37, by rule
Other programs on MC4R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| bremelanotiderule | palatin-technologies-inc | phase 4 | 8 |
| bivamelagonrule | Rhythm Pharmaceuticals | phase 2 | 3 |
| mifomelatiderule | endevica-bio | phase 2 | 2 |
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06772597Prader-Willi Syndrome · United States | 2 | Active, not recruiting | Nov 3, 2026 | 18 |
| NCT06760546Sexual Infantilism · United States, United Kingdom | 3 | Recruiting | Mar 13, 2027 | 39 |
| NCT06596135Obesity · United States | 3 | Completed | Jun 24, 2026 | 28 |
| NCT05774756Sexual Infantilism · United States, Canada, Germany and more | 3 | Active, not recruiting | Mar 18, 2025 | 143 |
| NCT05093634Obesity · United States, Canada, France and more | 3 | Completed | Dec 19, 2025 | 296 |
| NCT05046132Healthy · United States | 4 | Completed | Apr 7, 2022 | 77 |
| NCT05194124Bardet-Biedl Syndrome · United States, Canada, Germany and more | 3 | Completed | Oct 19, 2023 | 19 |
| NCT04963231Genetic Obesity · United States, Canada, Germany and more | 2 | Completed | Aug 4, 2023 | 164 |
| NCT04966741Bardet-Biedl Syndrome · United States, Australia, Spain and more | 3 | Completed | Sep 18, 2023 | 12 |
| NCT04725240Sexual Infantilism · United States | 2 | Completed | Jun 28, 2022 | 18 |
| NCT04348175Renal Insufficiency · United States | 1 | Completed | Apr 17, 2021 | 32 |
| NCT03746522Bardet-Biedl Syndrome · United States, Canada, France and more | 3 | Completed | Nov 16, 2020 | 52 |
| NCT03651765Obesity · United States, Canada, France and more | 3 | Completed | Jan 9, 2025 | 205 |
| NCT03287960Obesity · Canada, France, Germany and more | 3 | Completed | Sep 25, 2020 | 15 |
| NCT03262610Hypertriglyceridemia · United States | 2 | Completed | Jan 31, 2018 | 1 |
| NCT03013543Obesity · United States, Canada, France and more | 2 | Completed | Mar 1, 2022 | 213 |
| NCT02896192Obesity · United States, Belgium, Canada and more | 3 | Completed | May 25, 2020 | 15 |
| NCT02431442Overweight | 1 | Completed | Jan 2014 | 57 |
| NCT02311673Prader-Willi Syndrome · United States | 2 | Completed | Oct 26, 2016 | 40 |
| NCT02041195Overweight · United States | 2 | Completed | Aug 2014 | 99 |
| NCT01867437Obesity · United States | 1 | Completed | Mar 2014 | 15 |
| NCT01749137Overweight · United States | 2 | Completed | Sep 28, 2013 | 74 |
How it is read
Names in the registry
- “Setmelanotide”, 19 entries
- “RM-493”, 2 entries
- “Setmelanotide 2 mg”, 1 entry
- “Setmelanotide 2.5 mg”, 1 entry
- “Setmelanotide 3 mg”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 10 studies
- Sexual Infantilism, 3 studies
- Prader-Willi Syndrome, 2 studies
- Overweight, 2 studies
- Hypertriglyceridemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.